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ABSTRACT
Von Frey is used to quantify evoked allodynia in pain models for analgesic screening but is
susceptible to false positives. This research explored whether behavior in a novel arena apparatus with a
varied rough-textured floors in ½ fields might quantify spontaneous tactile allodynia and show better
predictive validity. Mice (C57BL/6) received 6 IP administrations of 2.3mg/kg of cisplatin over 12 days to
induce neuropathy (CIN). Behavioral measures were taken by eVF (g force to evoked stimuli) and arena
apparatus (movement and time in ½ fields) prior to and following ClN induction, and then 1-day later 30
min after each of 3 drug exposures (Saline, 3 mg/kg Oxycodone, and 100 mg/kg Gabapentin, IP) in a
Latin Square Design with 1-2 day drug holiday between testing. In eVF testing, cisplatin produced an
allodynic response that was attenuated by both oxycodone and gabapentin. In the arena apparatus,
cisplatin produced a reduction in overall movement that was attenuated only by oxycodone. Cisplatin
produced an increase in time spent on the 60 grit ½ field, but overall drug probes had inconsistent
effects on time spent on ½ field. In clinical populations, CIN is effectively treated with oxycodone but
not gabapentin. This novel arena apparatus, with a more translationally relevant spontaneous allodynia
endpoint, shows better predictive validity than eVF and may be useful in identifying novel
pharmacotherapies in oncology settings.

INTRODUCTION & BACKGROUND
Pain research relies on evoked
behavioral endpoints, such as those
measured by von Frey (VF), to quantify
allodynia in various chronic pain models
for analgesic screening but is susceptible
to false positives. False positives occur
when an animal assay predicts clinical
efficacy but the drug fails in clinical trials.
Such poor translational relevance may
reflect animal models/behavioral
endpoints that do not fully replicate

features of a clinical syndrome. This may
be particularly true with endpoints of
allodynia where its clinical presentation
is spontaneously evoked through normal
activity. This research explored whether
the behaviors of overall movement and
time spent in ½ fields in a novel tactile
arena apparatus with varied roughtextured floors might quantify
spontaneous tactile allodynia and show
better predictive validity in a model of
cisplatin-induced neuropathy (CIN).

MATERIAL & METHODS
Mice (C57BL/6) received 6 IP
administrations of 2.3mg/kg of cisplatin
over 12 days to induce neuropathy (CIN).
Behavioral measures were taken by
Topcat, MouseMet electronic-VF in g
force to an evoked stimuli and by Noldus
Ethovision overall movement and time
spent in ½ fields in an arena apparatus
containing 60 and 220 grit sandpaper in
each ½ fields (see below). These

endpoints were taken prior to and
following ClN induction and then 30 min
after each of 3 drug exposures (Saline, 3
mg/kg Oxycodone, and 100 mg/kg
Gabapentin, IP) in a Latin Square Design
with a 1-2 day drug holiday between
testing. Sample sizes were n = 12-14.
per group.

RESULTS

FIGURE 1. eVF: Cisplatin produced significant allodynia (†) that was significantly

attenuated (*) by both oxycodone and gabapentin on test sessions 2 and 3 (ps <
0.005).

FIGURE 2. Arena-Movement: Cisplatin produced significant decrease in movement (†)

that was significantly attenuated (*) by oxycodone and (**) gabapentin on test session
1 but only by oxycodone on test session 2 (ps < 0.005).

FIGURE 3. Arena-Time on ½ Field: Cisplatin produced a significant increase in spent

time in the 60-grit ½ field (*) that was significantly attenuated (†)only by gabapentin
on test session 1 (ps < 0.005).

DISCUSSION & CONCLUSION
In clinical populations, CIN is
effectively treated with oxycodone but
not gabapentin. This research found
that evoked responses from eVF were
sensitive to oxycodone and gabapentin
in attenuating allodynia induced by
CIN and, thus, susceptible to false
positives. The novel tactile arena was
most sensitive to oxycodone and only
modestly sensitive to gabapentin on
movement and only sensitive to
gabapentin on time in ½ field. This
tactile arena using changes in
movement may provide a more
translationally relevant measure of
allodynia than eVF. These findings
suggest this novel apparatus may be
useful in identifying novel analgesic
pharmacotherapies in oncology
settings.
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